title: Highly upregulated expression of CD36 and MSR1 in circulating monocytes of patients with acute coronary syndromes.
abstract: Acute Coronary Syndromes (ACS) are a group of disorders caused by the significant reduction of circulation in coronary arteries. The most common reason of the dysfunction is a blood clot formed in place of plaque rupture. The role of scavenger receptors in development and progression of atherosclerosis has been confirmed in many animal experiments, however the knowledge about contribution of the receptors in the development of ACS symptoms in humans still remains insufficient. The aim of this work was to define the expression of two scavenger receptors: CD36 and MSR1 in monocytes of patients with ACS after the onset of symptoms and after the 6 months of treatment. The analysis of CD36 and MSR1 expression was carried out with the use of real-time PCR and flow cytometry. Analyses of lipid and glucose concentration in blood and the level of inflammatory markers in plasma were performed additionally for all ACS patients. All data obtained during the research were analyzed using statistical tests, such as Mann Whitney test, Wilcoxon test, or correlation. In all patients with symptoms of ACS the amount of CD36 and MSR1 mRNA in circulating monocytes, as well as the density of both receptors on the cells surface was significantly higher. Re-analysis of subjects after 6 months of treatment, showed a significant decrease in the CD36 and MSR1 expression in all patients who received atorvastatin. The results of presented studies demonstrate that both investigated receptors are involved in the development and/or progression of ACS.
authors: Department of Animal Physiology and Development, Faculty of Biology, Adam Mickiewicz University, Umultowska 89 Str., 61-614 Poznan, Poland. piechota@amu.edu.pl
authors: Michal
authors: M
authors: Piechota
authors: Anna
authors: A
authors: Banaszewska
authors: Joanna
authors: J
authors: Dudziak
authors: Marek
authors: M
authors: Slomczynski
authors: Robert
authors: R
authors: Plewa
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood* / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000069059:Atorvastatin; D001786:Blood Glucose; D018955:CD36 Antigens / Q000235:genetics / Q000378:metabolism*; D016022:Case-Control Studies; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000378:metabolism*; D011758:Pyrroles / Q000627:therapeutic use; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction; D051117:Scavenger Receptors, Class A / Q000235:genetics / Q000378:metabolism*; D018709:Statistics, Nonparametric; D015854:Up-Regulation
chemical_list: D000924:Anticholesteremic Agents; D001786:Blood Glucose; D018955:CD36 Antigens; D006538:Heptanoic Acids; D008077:Lipoproteins, LDL; C495139:MSR1 protein, human; D011758:Pyrroles; D012333:RNA, Messenger; D051117:Scavenger Receptors, Class A; C099252:oxidized low density lipoprotein; D000069059:Atorvastatin